erinacine a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

erinacine A: stimulates biosynthesis of nerve growth factor; isolated from the mushroom Hericium erinaceum [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	10410568
CHEMBL ID	3797576
CHEBI ID	175499
SCHEMBL ID	21003843
MeSH ID	M000602907

Synonyms (13)

Synonym
CHEBI:175499
(3ar,5ar,6s)-3a,5a-dimethyl-1-propan-2-yl-6-[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy-2,3,4,5,6,7-hexahydrocyclohepta[e]indene-8-carbaldehyde
erinacine a
CHEMBL3797576
SCHEMBL21003843
156101-08-5
(3ar,5ar,6s)-3a,5a-dimethyl-1-(propan-2-yl)-6-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}-2h,3h,3ah,4h,5h,5ah,6h,7h-cyclohepta[e]indene-8-carbaldehyde
9L2H75S9XN
cyclohept[e]indene-8-carboxaldehyde, 2,3,3a,4,5,5a,6,7-octahydro-3a,5a-dimethyl-1-(1-methylethyl)-6-(beta-d-xylopyranosyloxy)-, (3ar,5ar,6s)-
(+)-erinacin a
(3ar,5ar,6s)-2,3,3a,4,5,5a,6,7-octahydro-3a,5a-dimethyl-1-(1-methylethyl)-6-(beta-d-xylopyranosyloxy)cyclohept[e]indene-8-carboxaldehyde
HY-111954
CS-0094438

Research Excerpts

Toxicity

Excerpt	Reference	Relevance
" No adverse or test article-related differences were found in urinalysis, haematology and serum biochemistry parameters, between the treatment and control groups."	( Evaluation of the toxicological safety of erinacine A-enriched Hericium erinaceus in a 28-day oral feeding study in Sprague-Dawley rats. Chen, CC; Chen, CS; Chen, WP; Chen, YL; Lee, LY; Li, IC; Tsai, YT, 2014)	0.67
" Conclusively, the obtained results suggested that EAHE mycelia could be relatively unharmful when used over an extended period, supporting its safe use in food preparation."	( Thirteen-Week Oral Toxicity Evaluation of Erinacine AEnriched Lion's Mane Medicinal Mushroom, Hericium erinaceus (Agaricomycetes), Mycelia in Sprague-Dawley Rats. Chen, CC; Chen, WP; Lee, LY; Li, IC; Tsai, YT; Tung, KC, 2019)	0.78

Bioavailability

Excerpt	Reference	Relevance
" HEM was cultivated via solid-state fermentation and micronized using cell wall-breaking technology to increase its bioavailability when ingested."	( Antioxidative Activities of Micronized Solid-State Cultivated Chiang, WC; Hsu, CH; Liao, EC; Wang, KL, 2023)	0.91

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

Class	Description
diterpenoid	Any terpenoid derived from a diterpene. The term includes compounds in which the C20 skeleton of the parent diterpene has been rearranged or modified by the removal of one or more skeletal atoms (generally methyl groups).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (4)

Assay ID	Title	Year	Journal	Article
AID1295869	Effect on neprilysin levels in cerebral cortex of APPswe/PSIdeltaE9 double transgenic C57BL/6J mouse at 30 mg/kg/day administered via oral gavage for 30 days by Western blot analysis	2016	Journal of natural products, Feb-26, Volume: 79, Issue:2	Erinacine S, a Rare Sesterterpene from the Mycelia of Hericium erinaceus.
AID1295867	Increase in nerve growth factor levels in cerebral cortex of APPswe/PSIdeltaE9 double transgenic C57BL/6J mouse at 30 mg/kg/day administered via oral gavage for 30 days	2016	Journal of natural products, Feb-26, Volume: 79, Issue:2	Erinacine S, a Rare Sesterterpene from the Mycelia of Hericium erinaceus.
AID1295866	Decrease in amyloid plaque burden in cerebral cortex of APPswe/PSIdeltaE9 double transgenic C57BL/6J mouse at 30 mg/kg/day administered via oral gavage for 30 days by AB10 staining based immunohistochemical assay	2016	Journal of natural products, Feb-26, Volume: 79, Issue:2	Erinacine S, a Rare Sesterterpene from the Mycelia of Hericium erinaceus.
AID1295868	Increase in insulin degrading enzyme in cerebral cortex of APPswe/PSIdeltaE9 double transgenic C57BL/6J mouse at 30 mg/kg/day administered via oral gavage for 30 days by Western blot analysis	2016	Journal of natural products, Feb-26, Volume: 79, Issue:2	Erinacine S, a Rare Sesterterpene from the Mycelia of Hericium erinaceus.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (22)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	14 (63.64)	24.3611
2020's	8 (36.36)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 30.99

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	30.99 (24.57)
Research Supply Index	3.14 (2.92)
Research Growth Index	4.65 (4.65)
Search Engine Demand Index	55.32 (26.88)
Search Engine Supply Index	3.13 (0.95)

This Compound (30.99)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	3 (13.64%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	19 (86.36%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine: A dopaminergic neurotoxic compound which produces irreversible clinical, chemical, and pathological alterations that mimic those found in Parkinson disease.. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine : A tetrahydropyridine that is 1,2,3,6-tetrahydropyridine substituted by a methyl group at position 1 and a phenyl group at position 4.	2.13	1	methylpyridines; phenylpyridine; tetrahydropyridine	neurotoxin
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one: specific inhibitor of phosphatidylinositol 3-kinase; structure in first source	2.17	1	chromones; morpholines; organochlorine compound	autophagy inhibitor; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; geroprotector
sucrose Saccharum: A plant genus of the family POACEAE widely cultivated in the tropics for the sweet cane that is processed into sugar.	2.21	1	glycosyl glycoside	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; osmolyte; Saccharomyces cerevisiae metabolite; sweetening agent
tyrosine Tyrosine: A non-essential amino acid. In animals it is synthesized from PHENYLALANINE. It is also the precursor of EPINEPHRINE; THYROID HORMONES; and melanin.. tyrosine : An alpha-amino acid that is phenylalanine bearing a hydroxy substituent at position 4 on the phenyl ring.	7.1	1	amino acid zwitterion; erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid; proteinogenic amino acid; tyrosine	EC 1.3.1.43 (arogenate dehydrogenase) inhibitor; fundamental metabolite; micronutrient; nutraceutical
glutamic acid Glutamic Acid: A non-essential amino acid naturally occurring in the L-form. Glutamic acid is the most common excitatory neurotransmitter in the CENTRAL NERVOUS SYSTEM.. glutamic acid : An alpha-amino acid that is glutaric acid bearing a single amino substituent at position 2.	2.41	1	glutamic acid; glutamine family amino acid; L-alpha-amino acid; proteinogenic amino acid	Escherichia coli metabolite; ferroptosis inducer; micronutrient; mouse metabolite; neurotransmitter; nutraceutical
3-nitrotyrosine 3-nitrotyrosine: RN given refers to parent cpd without isomeric designation. 3-nitrotyrosine : A nitrotyrosine comprising tyrosine having a nitro group at the 3-position on the phenyl ring.	2.1	1	2-nitrophenols; C-nitro compound; nitrotyrosine; non-proteinogenic alpha-amino acid
8-hydroxy-2'-deoxyguanosine 8-Hydroxy-2'-Deoxyguanosine: Common oxidized form of deoxyguanosine in which C-8 position of guanine base has a carbonyl group.. 8-hydroxy-2'-deoxyguanosine : Guanosine substituted at the purine 8-position by a hydroxy group. It is used as a biomarker of oxidative DNA damage.	2.31	1	guanosines	biomarker

Condition	Relationship Strength	Studies
Disease Exacerbation [description not available]	2.31	1
Amyloid Deposits [description not available]	2.63	2
Cognitive Decline [description not available]	2.31	1
Aging The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.	2.93	3
Cognitive Dysfunction Diminished or impaired mental and/or intellectual function.	2.31	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	3.17	4
Idiopathic Parkinson Disease [description not available]	3.57	2
Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)	3.57	2
Acute Brain Injuries [description not available]	2.41	1
Cerebral Ischemia [description not available]	2.58	2
Brain Injuries Acute and chronic (see also BRAIN INJURIES, CHRONIC) injuries to the brain, including the cerebral hemispheres, CEREBELLUM, and BRAIN STEM. Clinical manifestations depend on the nature of injury. Diffuse trauma to the brain is frequently associated with DIFFUSE AXONAL INJURY or COMA, POST-TRAUMATIC. Localized injuries may be associated with NEUROBEHAVIORAL MANIFESTATIONS; HEMIPARESIS, or other focal neurologic deficits.	2.41	1
Brain Ischemia Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION.	2.58	2
Autosomal Dominant Striatonigral Degeneration [description not available]	2.6	1
Machado-Joseph Disease A dominantly-inherited ATAXIA first described in people of Azorean and Portuguese descent, and subsequently identified in Brazil, Japan, China, and Australia. This disorder is classified as one of the SPINOCEREBELLAR ATAXIAS (Type 3) and has been associated with a mutation of the MJD1 gene on chromosome 14. Clinical features include progressive ataxia, DYSARTHRIA, postural instability, nystagmus, eyelid retraction, and facial FASCICULATIONS. DYSTONIA is prominent in younger patients (referred to as Type I Machado-Joseph Disease). Type II features ataxia and ocular signs; Type III features MUSCULAR ATROPHY and a sensorimotor neuropathy; and Type IV features extrapyramidal signs combined with a sensorimotor neuropathy. (From Clin Neurosci 1995;3(1):17-22; Ann Neurol 1998 Mar;43(3):288-96)	2.6	1
Cranial Nerve II Injuries [description not available]	2.6	1
Benign Neoplasms [description not available]	3.17	1
Nervous System Disorders [description not available]	3.17	1
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	3.17	1
Nervous System Diseases Diseases of the central and peripheral nervous system. This includes disorders of the brain, spinal cord, cranial nerves, peripheral nerves, nerve roots, autonomic nervous system, neuromuscular junction, and muscle.	3.17	1
Cancer of Stomach [description not available]	2.15	1
Stomach Neoplasms Tumors or cancer of the STOMACH.	2.15	1
Acute Confusional Senile Dementia [description not available]	3.77	3
Protein Aggregation, Pathological A biochemical phenomenon in which misfolded proteins aggregate either intra- or extracellularly. Triggered by factors such as MUTATION; POST-TRANSLATIONAL MODIFICATIONS, and environmental stress, it is generally associated with ALZHEIMER DISEASE; PARKINSON DISEASE; HUNTINGTON DISEASE; and TYPE 2 DIABETES MELLITUS.	2.17	1
Alzheimer Disease A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)	3.77	3
Hepatocellular Carcinoma [description not available]	2.17	1
Cancer of Liver [description not available]	2.17	1
Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.	2.17	1
Liver Neoplasms Tumors or cancer of the LIVER.	2.17	1
Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.	2.21	1
Degenerative Diseases, Central Nervous System [description not available]	2.21	1
Neurodegenerative Diseases Hereditary and sporadic conditions which are characterized by progressive nervous system dysfunction. These disorders are often associated with atrophy of the affected central or peripheral nervous system structures.	2.21	1
Diseases, Metabolic [description not available]	2.21	1
Metabolic Diseases Generic term for diseases caused by an abnormal metabolic process. It can be congenital due to inherited enzyme abnormality (METABOLISM, INBORN ERRORS) or acquired due to disease of an endocrine organ or failure of a metabolically important organ such as the liver. (Stedman, 26th ed)	2.21	1
Injury, Ischemia-Reperfusion [description not available]	2.1	1
Reperfusion Injury Adverse functional, metabolic, or structural changes in tissues that result from the restoration of blood flow to the tissue (REPERFUSION) following ISCHEMIA.	2.1	1
MPTP Neurotoxicity Syndrome [description not available]	2.13	1
Colorectal Cancer [description not available]	7.15	1
Invasiveness, Neoplasm [description not available]	2.15	1
Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.	2.15	1

chemdatabank.com